Recent research indicates that the spatial architecture of membrane proteins is crucial for regulating T-cell signaling and activation. 3-5 In the context of CAR T cells, the nanoscale localization ...
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) ...
Next-generation CAR T-cell therapies aim to improve accessibility, durability, and effectiveness, addressing current ...
Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% ...
Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback